Pascomer AFT Pharmaceuticals Pty Ltd
Product name
Pascomer
Sponsor
Accepted date
Apr-2026
Active ingredients
rapamycin/sirolimus
Summary of proposed indication
PASCOMER (rapamycin/sirolimus) is proposed for the treatment of facial angiofibromas associated with tuberous sclerosis complex.
Application type
C (new indication)
Publication date
Apr-2026
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.